Loading organizations...
§ Private Profile · Suzhou, Jiangsu, China
Biotechnology company developing and commercializing novel therapies for ocular diseases, focused on clinical-stage protein therapeutics.
Eluminex Biosciences is a biotechnology company that develops and commercializes novel therapies for ocular diseases, operating from its global headquarters in Suzhou, China, and a regional office in Mountain View, California. The organization focuses on advancing clinical-stage protein therapeutics, specifically targeting vision-threatening conditions like diabetic macular edema with its pentavalent trispecific fusion antibody known as EB-105. Additionally, the pipeline includes acquired oral therapies such as zuretinol acetate designed to treat various severe retinal conditions. To support the ongoing clinical advancement of its ophthalmic assets and proprietary recombinant human collagen technology, the enterprise has raised more than $40 million in Series B financing. This financial backing comes from a syndicate of prominent venture capital investors that includes Lilly Asia Ventures, Hillhouse Capital, and Quan Capital. Eluminex Biosciences was established in 2020 by founder Jinzhong Zhang.
Eluminex Biosciences has raised $90.0M across 2 funding rounds.
Eluminex Biosciences has raised $90.0M in total across 2 funding rounds.
Eluminex Biosciences has raised $90.0M across 2 funding rounds. Most recently, it raised $40.0M Series B in February 2023.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Feb 28, 2023 | $40M Series B | Cenova Capital | 3E Bioventures Capital, Oriza Holdings | Announced |
| Nov 30, 2020 | $50M Series A | Lilly Asia Ventures, Quan Capital | — | Announced |
Eluminex Biosciences has raised $90.0M in total across 2 funding rounds.
Eluminex Biosciences's investors include Cenova Capital, 3E Bioventures Capital, Oriza Holdings, Lilly Asia Ventures, Quan Capital.